title: Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?
abstract: BACKGROUND
  Early identification of true responders to acid suppression in functional dyspepsia patients with symptoms of epigastric pain or burning may enable clinicians to optimally tailor treatment.
  
  
  OBJECTIVE
  To evaluate whether a 1-w acid suppression trial is useful for identifying true responders in this population.
  
  
  METHODS
  Patients (18-70 years) were randomized to either esomeprazole 40 mg q.d.s., b.d. or placebo for 1w, and then esomeprazole 40 mg q.d.s. or placebo for 7w. Epigastric pain and/or burning were recorded on a 4-point scale (0 = none, 3 = severe). Trial-week response was defined as symptom score sum < or = 1 on last 3d of therapy; response at 8w was symptom score sum < or = 1 over preceding 7d.
  
  
  RESULTS
  1-w response rates were 33% (199 of 597), 29% (188 of 629) and 23% (71 of 315) with esomeprazole q.d.s., esomeprazole b.d. and placebo, respectively (P = 0.002 for esomeprazole groups vs. placebo). At 8w, trial week sensitivity and specificity were 46% and 80%, respectively, for esomeprazole (40 or 80 mg), and 33% and 87%, respectively, for placebo. The positive and negative predictive values for esomeprazole were 60% and 69%.
  
  
  CONCLUSIONS
  Response to a 1-w acid suppression trial is of limited use for predicting symptom response at 8w in patients with unexplained epigastric pain or burning.
authors: Mayo Clinic College of Medicine, Rochester, MN, USA. talley.nicholas@mayo.edu
authors: N J
authors: NJ
authors: Talley
authors: N
authors: N
authors: Vakil
authors: K
authors: K
authors: Lauritsen
authors: S V
authors: SV
authors: van Zanten
authors: N
authors: N
authors: Flook
authors: E
authors: E
authors: Bolling-Sternevald
authors: T
authors: T
authors: Persson
authors: E
authors: E
authors: Björck
authors: T
authors: T
authors: Lind
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004415:Dyspepsia / Q000188:drug therapy*; D064098:Esomeprazole / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000517:prevention & control; D006356:Heartburn / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011788:Quality of Life; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D010919:Placebos; D064098:Esomeprazole